Moderna Inc MRNA shares are trading higher on Monday. Piper Sandler boosted its price target on the stock to $69 from $63 while reiterating an Overweight rating. Here’s what you should know. Moderna ...

・BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares. ・The update followed the release of five-year follow-up results for the Intismeran vaccine used ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak.

Including the settlement payment, Moderna now expects to end 2026 with between $4.5 billion and $5 billion in cash and cash ...

Moderna stock is rising after the company agreed to pay up to $2.25 billion to settle a patent dispute over technology used ...

Moderna, Inc. (NASDAQ: MRNA) shares are swinging in volatile early trading on Friday, February 27, 2026, as investors digest ...

Moderna shares extend gains as FDA reverses its refusal-to-file decision on the firm’s influenza vaccine. Here’s why MRNA ...

Moderna Inc’s stock reached a significant milestone, hitting a 52-week high at 55.22 USD. This achievement underscores a robust performance over the past year, with the companys ...

Moderna Inc. MRNA shares are up during Wednesday’s premarket session following a settlement agreement with Arbutus Biopharma ...

This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.